Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-centre, Open-label, Study to Evaluate the Efficacy and Safety of WTX101 Administered for 24 Weeks in Newly Diagnosed Wilson Disease Patients Aged 18 and Older With an Extension Phase of 36 Months

NCT02273596 is registered in ClinicalTrials.gov with Alexion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02273596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02273596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-centre, Open-label, Study to Evaluate the Efficacy and Safety of WTX101 Administered for 24 Weeks in Newly Diagnosed Wilson Disease Patients Aged 18 and Older With an Extension Phase of 36 Months
Lead sponsor
Alexion Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 24, 2014
Completion date
November 7, 2018
Enrollment
29 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

wilson disease